{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:42:03Z","timestamp":1781149323558,"version":"3.54.1"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T00:00:00Z","timestamp":1499126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A newborn female child was born with a congenital pigment synthesizing melanoma of the scalp. Further workup revealed metastatic disease within the liver, lungs, and left tibia. Whole exome sequencing was performed on multiple samples that revealed one somatic mutation, lysine methyltransferase 2C (KMT2C), at low allelic frequency but no v\u2010Raf murine sarcoma viral oncogene homolog B (BRAF), NF\u20101 mutation. Programmed death ligand 1 was moderately expressed. Treatment was initiated with the programmed cell death protein 1 inhibitor nivolumab. The patient tolerated this treatment well with minimal toxicity. She is now over a year out from initial diagnosis, continuing on nivolumab, with stable disease.<\/jats:p>","DOI":"10.1002\/pbc.26702","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T14:31:50Z","timestamp":1499178710000},"source":"Crossref","is-referenced-by-count":9,"title":["PD\u20101 inhibition in congenital pigment synthesizing metastatic melanoma"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-8541","authenticated-orcid":false,"given":"Angela C.","family":"Weyand","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology and Oncology Department of Pediatrics and Communicable Diseases University of Michigan Medical Center  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajen J.","family":"Mody","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology Department of Pediatrics and Communicable Diseases University of Michigan Medical Center  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja M.","family":"Rabah","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Michigan Medical Center  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie P.","family":"Opipari","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology Department of Pediatrics and Communicable Diseases University of Michigan Medical Center  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10080"},{"key":"e_1_2_6_3_1","volume-title":"Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS","author":"NCI","year":"2009"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2524"},{"issue":"20","key":"e_1_2_6_5_1","first-page":"347","article-title":"Skin tumors in childhood","volume":"108","author":"Hamm H","year":"2011","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1542\/peds.55.2.191","article-title":"Metastatic malignant melanoma in prepubertal children","volume":"55","author":"Trozak DJ","year":"1975","journal-title":"Pediatrics"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2004.01975.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2006.02411.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.016"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198056"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2123"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0143"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2550"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.26702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:55:38Z","timestamp":1696035338000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.26702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,4]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/pbc.26702"],"URL":"https:\/\/doi.org\/10.1002\/pbc.26702","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,4]]},"article-number":"e26702"}}